近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-03 | 21.30 0.42% | | 2118.31万 | 13.39% | 1423.55万 | 9.00% | -3541.86万 | -22.38% | | 2025-12-02 | 21.21 0.09% | | -200.72万 | -3.54% | 260.69万 | 4.59% | -59.96万 | -1.06% | | 2025-12-01 | 21.19 | -0.19% | -232.84万 | -3.84% | -20.18万 | -0.33% | 253.02万 | 4.17% | | 2025-11-28 | 21.23 | 0.66% | -121.73万 | -1.81% | 164.01万 | 2.43% | -42.29万 | -0.63% | | 2025-11-27 | 21.09 | 0 ...

Core Viewpoint - The stock of Meihao Medical (301363) has shown a slight increase in price, with a notable net inflow of main funds, indicating positive market sentiment despite some outflows from retail investors [1][2]. Financial Performance - As of November 13, 2025, Meihao Medical's stock closed at 22.22 yuan, up by 1.05% with a trading volume of 84,500 hands and a total transaction amount of 185 million yuan [1]. - For the first three quarters of 2025, the company reported a main revenue of 1.194 billion yuan, a year-on-year increase of 3.28%, while the net profit attributable to shareholders was 208 million yuan, down by 19.25% [3]. - The third quarter of 2025 saw a single-quarter main revenue of 462 million yuan, up by 2.56%, and a net profit of 93.90 million yuan, up by 5.89% [3]. Market Position and Ratios - Meihao Medical's total market capitalization is 12.64 billion yuan, with a net asset value of 3.702 billion yuan and a net profit of 208 million yuan [3]. - The company's price-to-earnings ratio (P/E) is 45.53, which is lower than the industry average of 60.24, while the price-to-book ratio (P/B) stands at 3.41, also below the industry average of 4.15 [3]. - The gross margin is reported at 39.34%, significantly lower than the industry average of 51.22%, while the net margin is 17.43%, higher than the industry average of 9.57% [3]. Investment Sentiment - Over the past 90 days, 18 institutions have rated the stock, with 16 buy ratings and 2 hold ratings, indicating strong institutional support [4]. - The average target price set by institutions over the last 90 days is 25.20 yuan, suggesting potential upside from the current trading price [4].

Core Viewpoint - The stock of Meihao Medical (301363) has shown a slight increase in price, with a closing price of 21.8 yuan on November 10, 2025, reflecting a 0.65% rise, despite a net outflow of main funds [1][2]. Financial Performance - For the first three quarters of 2025, Meihao Medical reported a main revenue of 1.194 billion yuan, a year-on-year increase of 3.28%, while the net profit attributable to shareholders was 208 million yuan, a decrease of 19.25% [3]. - In Q3 2025, the company achieved a single-quarter main revenue of 462 million yuan, up 2.56% year-on-year, and a net profit of 93.9 million yuan, an increase of 5.89% year-on-year [3]. Market Position - Meihao Medical's total market capitalization is 12.401 billion yuan, with a net asset value of 3.702 billion yuan and a net profit of 208 million yuan, ranking 27th in the medical device industry [3]. - The company's price-to-earnings ratio (P/E) is 44.67, which is lower than the industry average of 62.58, while the price-to-book ratio (P/B) stands at 3.35, also below the industry average of 4.04 [3]. Fund Flow Analysis - On November 10, 2025, the main funds experienced a net outflow of 4.2463 million yuan, accounting for 5.82% of the total transaction amount, while retail investors saw a net inflow of 3.3461 million yuan, representing 4.58% of the total transaction amount [1][2]. - Over the past five days, the stock has seen fluctuating fund flows, with significant outflows from main funds on several days, indicating a mixed sentiment among investors [2]. Analyst Ratings - In the last 90 days, 17 institutions have rated Meihao Medical, with 15 buy ratings and 2 hold ratings, and the average target price set by institutions is 25.2 yuan [4].

Core Viewpoint - The stock of Meihao Medical (301363) has shown a slight decline, with recent trading data indicating mixed capital flows and performance metrics compared to industry averages [1][2][3]. Group 1: Stock Performance - As of October 16, 2025, Meihao Medical's stock closed at 23.13 yuan, down 0.04%, with a trading volume of 57,800 hands and a total transaction amount of 134 million yuan [1]. - The net inflow of main funds on October 16 was 13.05 million yuan, accounting for 9.72% of the total transaction amount, while retail investors experienced a net outflow of 10.73 million yuan, representing 8.00% of the total [1][2]. Group 2: Financial Metrics - Meihao Medical's total market value is 13.158 billion yuan, with a net asset of 3.595 billion yuan and a net profit of 114 million yuan [3]. - The company's revenue for the first half of 2025 was 733 million yuan, a year-on-year increase of 3.73%, while the net profit decreased by 32.44% to 114 million yuan [3]. - The gross profit margin stands at 37.52%, which is significantly lower than the industry average of 51.85% [3]. Group 3: Industry Comparison - In terms of valuation, Meihao Medical has a price-to-earnings ratio of 57.56, which is lower than the industry average of 66.63, and a price-to-book ratio of 3.66, compared to the industry average of 3.81 [3]. - The company ranks 25th in total market value and 42nd in net assets within the medical device industry [3]. Group 4: Analyst Ratings - Over the past 90 days, 17 institutions have rated Meihao Medical, with 15 buy ratings and 2 hold ratings, indicating a generally positive outlook [4]. - The average target price set by institutions for the stock is 24.42 yuan [4].

Core Viewpoint - The stock of Meihao Medical (301363) has experienced a decline, with a closing price of 26.06 yuan on September 12, 2025, down by 1.88% [1] Group 1: Stock Performance and Trading Data - On September 12, 2025, the stock had a turnover rate of 6.82%, with a trading volume of 106,500 hands and a transaction amount of 278 million yuan [1] - The net inflow of main funds was 31.17 million yuan, accounting for 7.33% of the total transaction amount, while retail investors saw a net outflow of 10.76 million yuan, representing 2.53% of the total [1] - Over the past five days, the stock has shown fluctuating performance, with a notable increase in main fund inflow on September 10, 2025, amounting to 33.34 million yuan, which was a 6.98% increase in stock price [2] Group 2: Financial Metrics and Industry Comparison - Meihao Medical's total market value is 14.995 billion yuan, with a net asset of 3.595 billion yuan and a net profit of 114 million yuan, ranking 23rd, 42nd, and 40th respectively in the medical device industry [3] - The company's revenue for the first half of 2025 was 733 million yuan, a year-on-year increase of 3.73%, while the net profit decreased by 32.44% to 114 million yuan [3] - The gross profit margin stands at 37.52%, significantly lower than the industry average of 51.85%, indicating potential challenges in profitability [3] Group 3: Analyst Ratings and Market Sentiment - In the last 90 days, 17 institutions have rated the stock, with 15 buy ratings and 2 hold ratings, suggesting a generally positive outlook among analysts [4] - The average target price set by institutions over the past 90 days is 26.48 yuan, indicating a slight upside potential from the current trading price [4]

Group 1 - The stock of Meihao Medical (301363) closed at 24.6 yuan on September 3, 2025, down 1.4% with a turnover rate of 9.95% and a trading volume of 155,500 hands, resulting in a transaction amount of 387 million yuan [1] - On September 3, 2025, the net inflow of main funds was 23.1 million yuan, accounting for 5.97% of the total transaction amount, while retail investors had a net outflow of 27.2 million yuan, accounting for 7.03% [1] - Over the past five days, the stock has experienced fluctuations in both main and retail fund flows, with notable changes in net inflows and outflows [1] Group 2 - Meihao Medical's total market value is 13.994 billion yuan, which is higher than the industry average of 11.994 billion yuan, ranking 24th out of 123 in the medical device industry [2] - The company's net profit for the first half of 2025 was 114 million yuan, a decrease of 32.44% year-on-year, while its main revenue was 733 million yuan, an increase of 3.73% year-on-year [2] - The company reported a gross profit margin of 37.52%, which is significantly lower than the industry average of 51.85%, ranking 93rd out of 123 [2] Group 3 - In the last 90 days, 16 institutions have rated the stock, with 14 buy ratings and 2 hold ratings, and the average target price set by institutions is 26.48 yuan [3]

Core Viewpoint - As of September 1, 2025, Meihao Medical (301363) closed at 25.21 yuan, marking a 4.65% increase, with significant trading activity and mixed capital flows [1][2]. Group 1: Stock Performance - On September 1, 2025, the stock price increased by 4.65% with a trading volume of 271,900 hands and a total transaction amount of 671 million yuan [1]. - The stock experienced a net inflow of 75.38 million yuan from main funds, accounting for 11.23% of the total transaction amount, while retail investors saw a net outflow of 110 million yuan, representing 16.39% of the total [1][2]. Group 2: Financing and Margin Trading - On September 1, 2025, the financing buy amounted to 81.20 million yuan, with a net financing buy of 715,000 yuan, while the margin trading balance stood at 1.59 billion yuan [2][3]. - The stock's margin trading data indicated a total of 3.72 million shares in margin trading, with a margin balance of 937,300 yuan [3]. Group 3: Financial Metrics and Industry Comparison - Meihao Medical reported a total market value of 14.34 billion yuan, with a net profit of 114 million yuan, reflecting a year-on-year decline of 32.44% [5]. - The company's gross profit margin was 37.52%, significantly lower than the industry average of 51.85%, while its net profit margin was 15.6%, higher than the industry average of 10.39% [5]. - The company’s return on equity (ROE) was 3.23%, outperforming the industry average of 1.8% [5]. Group 4: Institutional Ratings - In the last 90 days, 16 institutions rated the stock, with 14 buy ratings and 2 hold ratings, and the average target price set at 26.48 yuan [6].

Core Viewpoint - The stock of Meihao Medical (301363) has experienced a decline, with a closing price of 25.16 yuan on August 28, 2025, down 1.64% from the previous day, indicating a volatile trading environment and mixed investor sentiment [1]. Financial Performance - For the first half of 2025, Meihao Medical reported a main revenue of 733 million yuan, a year-on-year increase of 3.73%, while the net profit attributable to shareholders was 114 million yuan, a decrease of 32.44% [3]. - In Q2 2025, the company achieved a single-quarter main revenue of 437 million yuan, up 2.86% year-on-year, but the net profit attributable to shareholders fell by 43.83% to 62.43 million yuan [3]. - The company's gross profit margin stands at 37.52%, which is significantly lower than the industry average of 51.86% [3]. Market Position and Valuation - Meihao Medical's total market capitalization is 14.31 billion yuan, which is above the industry average of 12.06 billion yuan, ranking 23rd out of 123 companies in the medical device sector [3]. - The company's price-to-earnings (P/E) ratio is 62.61, which is lower than the industry average of 70.48, ranking 63rd in the industry [3]. - The price-to-book (P/B) ratio is 3.98, slightly above the industry average of 3.89, ranking 86th [3]. Investor Sentiment and Fund Flow - On August 28, 2025, the net outflow of main funds was 31.03 million yuan, accounting for 5.15% of the total transaction volume, while retail investors saw a net inflow of 29.83 million yuan, representing 4.95% of the total [1][2]. - Over the past 90 days, 15 institutions have rated the stock, with 13 buy ratings and 2 hold ratings, indicating a generally positive outlook among analysts [4].